以色列衛生部:復必泰預防Delta變種感染及病徵有效率下跌
《路透》報道,以色列衛生部發表報告指,輝瑞(PFE.US)及BioNTech研發的復必泰新冠疫苗,應對Delta變種新冠的效力較低。其中在防止感染或出現病徵的效力降低,但對防止嚴重病例上高度有效。
報告指,疫苗對預防感染及有病徵個案的有效率自6月6日以來降至64%,但在預防入院及嚴重疾病個案的有效率爲93%。當局5月數據顯示,接種兩劑復必泰疫苗可對防止感染、入院及嚴重疾病有95%保護率。
以色列930萬人口中,約六成已接種最少一劑復必泰,單日新增確診數字亦由1月的逾萬宗減至上月初的少於十宗。但在當地放寬社交限制後,確診數字回升,週日(4日)單日新增343宗,嚴重個案亦由21宗升至35宗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.